FDA Approves Treg Cell Therapy - Top-Institutions - MDSpire

FDA Approves Treg Cell Therapy

A randomized clinical trial found higher chronic GVHD-free survival and lower rates of serious chronic GVHD compared with standard transplantation in adults with blood cancers.

  • By

  • Kathryn Wighton

  • July 1, 2026

  • 2 min

Share

Top Institutions in Internal Medicine

Brief introduction explaining scope and methodology.

  • #1

    Stanford University School of Medicine / Stanford Health Care
    Stanford University School of Medicine / Stanford Health Care

    Stanford, California

    Key Differentiators

    • Immunology
    • Hematology
    • Oncology

  • #2

    City of Hope National Medical Center
    City of Hope National Medical Center

    Duarte, California

    Key Differentiators

    • Immunology
    • Hematology
    • Oncology

  • #3

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, Massachusetts

    Key Differentiators

    • Immunology
    • Oncology

  • #4

    Hospital of the University of Pennsylvania
    Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania

    Key Differentiators

    • Immunology
    • Oncology

  • #5

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, Massachusetts

    Key Differentiators

    • Immunology
    • Oncology

Original Source(s)

FDA Approves Treg Cell Therapy

  • by Kathryn Wighton

  • July 1, 2026

Related Content

Cell Aging May Predict Future Disease

Plasma proteomic models of more than 40 cell types were associated with incident Alzheimer's disease, amyotrophic lateral sclerosis, cancer,  and mortality across three large cohorts.

Oral Carbapenem Wins FDA Approval for cUTIs

Tebipenem pivoxil was noninferior to intravenous imipenem-cilastatin in hospitalized adults.

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.